Sanofi has discontinued development of its next-generation mRNA-based seasonal flu vaccine.
According to its 2025 earnings documents, the drugmaker said it halted its phase 1 trial for an mRNA seasonal influenza vaccine and does not anticipate launching an mRNA-based seasonal flu product in the near term.
Sanofi said it will continue developing an mRNA-based pandemic flu vaccine. The company is conducting a phase 1/2 study of an mRNA vaccine using an H5 avian flu platform, which it said has shown encouraging preliminary data.
The company previously said it was working on next-generation mRNA seasonal flu vaccines in June 2023, bringing five different lipids into clinical trials, according to a Jan. 30 news release from the Center for Infectious Disease Research and Policy at the University of Minnesota, which is based in Minneapolis. Sanofi acquired mRNA-focused Translate Bio in 2021 for $3.2 billion as part of its broader investment in mRNA technology.
Sanofi said it remains focused on its existing influenza portfolio, including Fluzone High-Dose and Flublok, both of which are approved by the FDA and target protection against severe flu outcomes.
